NASDAQ:VSTM - Verastem Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.07 -0.43 (-5.06 %)
(As of 07/16/2018 12:06 PM ET)
Previous Close$8.51
Today's Range$8.01 - $8.51
52-Week Range$2.77 - $9.07
Volume51,062 shs
Average Volume4.33 million shs
Market Capitalization$487.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51
Verastem logoVerastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. Its defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. The company also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with hematologic cancers through the dual inhibition of PI3K delta and gamma. Its duvelisib is in Phase 3 randomized and late-and mid-stage clinical trials for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with double-refractory indolent non-Hodgkin lymphoma. The company has license agreements with Infinity Pharmaceuticals, Inc.; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Debt-to-Equity Ratio0.39
Current Ratio4.45
Quick Ratio4.45

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.19 per share
Price / Book6.78

Profitability

EPS (Most Recent Fiscal Year)($1.76)
Net Income$-67,800,000.00
Net MarginsN/A
Return on Equity-163.60%
Return on Assets-107.14%

Miscellaneous

Employees69
Outstanding Shares57,310,000
Market Cap$487.11

The Truth About Cryptocurrencies

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) issued its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.02. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

9 brokers have issued 1-year price targets for Verastem's shares. Their forecasts range from $10.00 to $17.00. On average, they anticipate Verastem's stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 79.5% from the stock's current price. View Analyst Ratings for Verastem.

What is the consensus analysts' recommendation for Verastem?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:
  • 1. Cann analysts commented, "We rate Verastem, a clinical-stage biotechnology company, Outperform and we are increasing our price target to account for an increased average forward price-to-sales multiple of the biotechnology sector." (7/9/2018)
  • 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5." (5/3/2018)
  • 3. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (3/20/2018)
  • 4. Cantor Fitzgerald analysts commented, "Working off Overhangs. We think VSTM shares are undervalued relative to the duvelisib opportunity, and this is partly a function, in our view, of overhangs, particularly cash. VSTM had just under $87 mln in cash, which is sufficient to fund the company into 2H18, but will need additional capital to see duvelisib through commercialization. VSTM has an additional $35 mln available under a debt facility, and the company could add additional cash through a partner deal. It has been our anticipation that VSTM will need to address the capital markets in some way in 2018." (3/13/2018)

Are investors shorting Verastem?

Verastem saw a increase in short interest in June. As of June 29th, there was short interest totalling 7,308,173 shares, an increase of 227.4% from the June 15th total of 2,232,306 shares. Based on an average trading volume of 6,233,487 shares, the short-interest ratio is presently 1.2 days. Currently, 10.4% of the shares of the company are sold short. View Verastem's Current Options Chain.

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 54)
  • Ms. Julie B. Feder, Chief Financial Officer (Age 47)
  • Dr. NgocDiep T Le M.D., Ph.D., Chief Medical Officer (Age 50)
  • Mr. Richard H. Aldrich, Founder and Consultant (Age 64)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board

Has Verastem been receiving favorable news coverage?

Headlines about VSTM stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Verastem earned a news sentiment score of 0.09 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 48.13 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $8.08.

How big of a company is Verastem?

Verastem has a market capitalization of $487.11 million. The biopharmaceutical company earns $-67,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Verastem employs 69 workers across the globe.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]


MarketBeat Community Rating for Verastem (NASDAQ VSTM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.